{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=42&state=Alabama",
    "query": {
      "state": "Alabama",
      "city": "Birmingham",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 9514,
    "total_pages": 952,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=43&state=Alabama&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Birmingham&page=41&state=Alabama&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T11:04:44.639Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07150923",
      "title": "Supraglottic Airway for Resuscitation Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neonatal Resuscitation",
        "Delivery Room Resuscitation",
        "Positive Pressure Ventilation",
        "Infant, Newborn",
        "Supraglottic Airway",
        "Laryngeal Mask Airways",
        "Implementation Research"
      ],
      "interventions": [
        {
          "name": "Enhanced Standard of Care (\"Enhanced\")",
          "type": "OTHER"
        },
        {
          "name": "Enhanced Standard of Care (\"Enhanced-Plus\")",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Days and older"
      },
      "enrollment_count": 36503,
      "start_date": "2026-01-01",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Chula Vista, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07150923"
    },
    {
      "nct_id": "NCT05042362",
      "title": "A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Vasomotor Symptoms Associated With Menopause",
        "Hot Flashes"
      ],
      "interventions": [
        {
          "name": "Elinzanetant (BAY3427080)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "40 Years to 65 Years · Female only"
      },
      "enrollment_count": 396,
      "start_date": "2021-08-27",
      "completion_date": "2023-11-27",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05042362"
    },
    {
      "nct_id": "NCT03911388",
      "title": "HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms, Brain",
        "Glioblastoma Multiforme",
        "Glioblastoma of Cerebellum",
        "Neoplasms",
        "Astrocytoma",
        "Astrocytoma, Cerebellar",
        "Neuroectodermal Tumors",
        "Neuroectodermal Tumors, Primitive",
        "Cerebellar PNET, Childhood",
        "Cerebellar Neoplasms",
        "Cerebellar Neoplasms, Primary",
        "Cerebellar Neoplasm, Malignant",
        "Cerebellar Neoplasm Malignant Primary",
        "Neoplasm Metastases",
        "Neoplasm Malignant",
        "Neoplasms, Neuroepithelial",
        "Neoplasms, Germ Cell and Embryonal",
        "Neoplasms by Histologic Type",
        "Neoplasms, Glandular and Epithelial",
        "Neoplasms, Nerve Tissue",
        "Central Nervous System Neoplasms, Primary",
        "Central Nervous System Neoplasms, Malignant",
        "Nervous System Neoplasms",
        "Neoplasms by Site",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Nervous System Diseases",
        "Medulloblastoma Recurrent",
        "HSV",
        "Virus",
        "Pediatric Brain Tumor",
        "Nervous System Cancer",
        "Primitive Neuroectodermal Tumor (PNET) of Cerebellum"
      ],
      "interventions": [
        {
          "name": "G207",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "36 Months",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "36 Months to 22 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-09-12",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03911388"
    },
    {
      "nct_id": "NCT01259388",
      "title": "A Pilot Study of Lithium in Progressive Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Lithium Carbonate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 23,
      "start_date": "2011-05",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01259388"
    },
    {
      "nct_id": "NCT00318903",
      "title": "Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer",
        "Cancer of the Esophagus",
        "Esophagus Cancer",
        "Esophageal Neoplasm",
        "Cancer of Esophagus"
      ],
      "interventions": [
        {
          "name": "Irinotecan (drug)",
          "type": "DRUG"
        },
        {
          "name": "Taxotere (drug)",
          "type": "DRUG"
        },
        {
          "name": "Radiotherapy (procedure)",
          "type": "PROCEDURE"
        },
        {
          "name": "Esophagectomy (procedure)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2002-01",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2023-05-25",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00318903"
    },
    {
      "nct_id": "NCT00441727",
      "title": "Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Ulcer",
        "Duodenal Ulcer"
      ],
      "interventions": [
        {
          "name": "Esomeprazole 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2426,
      "start_date": "2007-02",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441727"
    },
    {
      "nct_id": "NCT01255761",
      "title": "A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol (CZP)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 736,
      "start_date": "2010-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 110,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255761"
    },
    {
      "nct_id": "NCT03377361",
      "title": "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Tumors",
        "Colorectal Carcinoma",
        "Colorectal Neoplasm"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 325,
      "start_date": "2018-01-31",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03377361"
    },
    {
      "nct_id": "NCT01470469",
      "title": "SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Generalized Anxiety Disorder (GAD)",
        "Anxiety, Separation",
        "Phobia, Social"
      ],
      "interventions": [
        {
          "name": "SPD503 (extended-release Guanfacine hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 83,
      "start_date": "2012-01-04",
      "completion_date": "2013-07-15",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Carson, California • Imperial, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Carson",
          "state": "California"
        },
        {
          "city": "Imperial",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01470469"
    },
    {
      "nct_id": "NCT01582269",
      "title": "A Study in Recurrent Glioblastoma (GB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Galunisertib",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2012-04-26",
      "completion_date": "2024-10-10",
      "has_results": true,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-21T11:04:44.639Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582269"
    }
  ]
}